This is normal biological variation, not a personal failure
Genetic differences in GLP-1 receptor sensitivity and remaining beta cell function significantly affect individual treatment response
If a practice lacks this capacity, patients may be better served by weight management specialists or other providers with dedicated GLP-1 programs
In 2025, Novo Nordisk submitted Orforglipron for regulatory review by the FDA, but it is not yet approved
If you have been recommended to take this medication because there are no alternatives for you, please get in touch with the Drugs in Breastmilk Team to discuss information available that you can use to discuss risks and benefits of your treatment choices with your healthcare professional to make an informed decision for the health of you and your child
We thank the Shanghai Municipal Government, ShanghaiTech University and GPCR Consortium for financial support